Maddocks advises ANSTO on radiopharma licence agreement with ITM
Maddocks has advised the Australian Nuclear Science and Technology Organisation (ANSTO) on a new long-term IP and technology licence agreement with leading German radiopharmaceutical biotech company ITM Isotope Technologies Munich SE (ITM).
Under the agreement, ANSTO will continue to produce medical radioisotope n.c.a. Lutetium-177 (n.c.a. 177Lu) for the Australian and New Zealand markets using ITM’s production technology. N.c.a. 177Lu is used as a radiopharmaceutical precursor in Targeted Radionuclide Therapy, a novel treatment regimen in precision oncology.
The continuation of ANSTO’s long-standing partnership with ITM is significant as it allows local manufacturing to continue to support growing demand of patients in the Australia-New Zealand region.
The Maddocks team was led by IP and life sciences partner Ben Miller, with assistance from lawyer Sophie Vo and our IP and pharma regulatory team.
Maddocks is a proudly independent Australian law firm that works closely with corporations, businesses and governments throughout Australia and internationally. We advise national and international clients across the education, government, healthcare, infrastructure and technology sectors, from our Canberra, Melbourne and Sydney offices. Our specialist expertise includes intellectual property, life sciences, dispute resolution and litigation, employment and safety, financial services, franchising and insolvency.
For more information:
Tel: 03 9258 3509
Mobile: 0407 618 058
Maddocks advises Origin Energy on solar farm acquisitions
Maddocks has advised major integrated energy company Origin Energy on its acquisition of the Yarrabee Solar Farm...
Maddocks advises Swoop on latest key acquisition
Maddocks has advised Swoop Holdings Limited on its acquisition of Sydney-based Luminet.
The regulation roadmap: Maddocks provides insights for the year ahead in its annual ACCC Year in Review
We have released our annual review of the performance of the ACCC against its own enforcement priorities
Maddocks advises Navis Capital Partners on latest acquisition
We have advised Australian private equity group Navis Capital Partners on the acquisition of Software Combined.